跳至主要内容
临床试验/NCT06068673
NCT06068673已完成不适用

The Potential Impact of Clindamycin on Neurosurgery Patients.

Damanhour University1 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2023年3月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
44
试验地点
1
主要终点
Neuron-specific enolase (NSE) Blood Concentration

研究概览

简要总结

A prospective, open-label, single center, controlled trial. 44 patients that underwent neurosurgery or presented meningitis signs, for whom Clindamycin add-on therapy to assess its effect on neurological complication in relation to Neuron-specific enolase (NSE) and Neurotensin biomarkers levels.

详细描述

  1. This is a prospective, open-label, single center, controlled trial. 44 patients that underwent neurosurgery or presented meningitis signs, for whom Clindamycin add-on therapy is prescribed (900 - 1200 mg twice daily) will be recruited from Alexandria University Main Hospital.
  2. Whole blood samples will be collected for Analyses of Neuron-specific enolase (NSE) and Neurotensin will be detected by ELISA.
  3. All patients will be assessed for complete blood count (CBC), kidney function, liver function, Methodology
  • Patients will be enrolled if they underwent surgery or presented with clinical signs of meningitis.
  • All enrolled 44 patients will be divided into two groups; Group I are patients who will receive clindamycin added-on therapy. Group II patients will be managed with the standard regimen.
  • Complete physical, laboratory, and radiological assessment will be done for all patients
  • All patients will be followed up during 2 weeks period.
  • Serum samples will be collected for measuring the biomarkers.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Group A

Experimental

Group I are patients who will receive clindamycin added-on therapy.

干预措施: Clindamycin 600 mg (Drug)

Group B

Active Comparator

Group II patients will be managed with the standard regimen.

干预措施: standard regimen (Drug)

结局指标

主要结局

Neuron-specific enolase (NSE) Blood Concentration

时间窗: 2 weeks

Serum Level of NSE pg/ml

Neurotensin Blood Concentration

时间窗: 2 Weeks

Serum Level of Neurotensin pg/ml

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Rehab Werida

Associate Professor

Damanhour University

研究点 (1)

Loading locations...

相似试验